Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at …

Furthermore, it will highlight the impact of ensifentrine treatment on healthcare resource utilization related to COPD including fewer physician’s …

Share on Facebook

Tweet

Follow us

Save